6'-Hydroxycinchonin | 524-63-0

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 金鸡纳生物碱
• 英文名称: 6'-Hydroxycinchonin
• 英文别名: 4-[(S)-(5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl)-hydroxymethyl]quinolin-6-ol
• CAS: 524-63-0；70877-75-7
• 化学式: C₁₉H₂₂N₂O₂
• 分子量: 310.396
• InChiKey: VJFMSYZSFUWQPZ-XIPJALCNSA-N

物化性质

• 熔点：
  >171°C (dec.)
• 比旋光度：
  D17 -176°
• 沸点：
  450.55°C (rough estimate)
• 密度：
  1.1396 (rough estimate)
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  56.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090

文献信息

• [EN] DOPAMINE-Β-HYDROXYLASE INHIBITORS<br/>[FR] INHIBITEURS DE DOPAMINE-B-HYDROXYLASE
  申请人：BIAL PORTELA & Cª S A

  公开号：WO2020246903A1

  公开（公告）日：2020-12-10

  This invention relates to: (a) compounds of formula I (with R1 to R5 and A as defined herein) and pharmaceutically acceptable salts or solvates thereof that are useful as dopamine-β-hydroxylase inhibitors; (b) pharmaceutical compositions comprising such compounds, salts or solvates; (c) the use of such compounds, salts or solvates in therapy; (d) therapeutic methods of treatment using such compounds, salts or solvates; and (e) processes and intermediates useful for the synthesis of such compounds.

  本发明涉及：(a) 公式I中的化合物（其中R1至R5和A如本文所定义）及其药用可接受的盐或溶剂，这些化合物可用作多巴胺-β-羟化酶抑制剂；(b) 包括这些化合物、盐或溶剂的药物组合物；(c) 使用这些化合物、盐或溶剂进行治疗；(d) 使用这些化合物、盐或溶剂进行治疗的治疗方法；以及(e) 用于合成这些化合物的过程和中间体。
• Transformation of meso-lactide
  申请人：Colorado State University Research Foundation

  公开号：US10174161B2

  公开（公告）日：2019-01-08

  B/N Lewis pairs have been discovered to catalyze rapid epimerization of meso-lactide (LA) or LA diastereomers quantitatively into rac-LA. The obtained rac-LA can be kinetically polymerized into poly(L-lactide) and optically resolved D-LA, with a high stereoselectivity factor kL/kD of 53 and an ee value of 91% at 50.6% monomer conversion, by a bifunctional chiral catalyst. The epimerization and enantioselective polymerization can be coupled into a one-pot process for transforming meso-LA directly into poly(L-lactide) and D-LA.

  研究发现，B/N Lewis 对可催化中-内酰胺（LA）或 LA 非对映异构体快速外嵌合，定量生成 rac-LA。在双功能手性催化剂的作用下，得到的 rac-LA 可被动力学聚合成聚（L-内酰胺）和光学分辨的 D-LA，立体选择性系数 kL/kD 高达 53，在单体转化率为 50.6% 时，ee 值为 91%。表聚和对映体选择性聚合可以耦合为一个一锅工艺，直接将介壳烯烃转化为聚（L-内酰胺）和 D-LA。
• Antifungal compound process
  申请人：MYCOVIA PHARMACEUTICALS INC.

  公开号：US10836740B2

  公开（公告）日：2020-11-17

  The present invention relates to a process for preparing a compound of 5 or 5*, or a mixture thereof, that is useful as an antifungal agent. In particular, the invention seeks to provide new methodology for preparing compounds 7 or 7* and 11 or 11* and substituted derivatives thereof.

  本发明涉及一种制备可用作抗真菌剂的 5 或 5* 类化合物或其混合物的工艺。特别是，本发明试图提供制备化合物 7 或 7* 和 11 或 11* 及其取代衍生物的新方法。
• Cinchonium betaine catalysts and methods of using same
  申请人：Brandeis University

  公开号：US10888853B2

  公开（公告）日：2021-01-12

  Provided herein are cinchonium betaine catalysts and methods of promoting asymmetric imine isomerization reactions using the same.

  本文提供了金鸡纳铵甜菜碱催化剂以及使用该催化剂促进不对称亚胺异构化反应的方法。
• Asymmetric carbon-carbon-bond-forming reactions catalyzed by bifunctional cinchona alkaloids
  申请人：Deng Li

  公开号：US20070083049A1

  公开（公告）日：2007-04-12

  One aspect of the present invention relates to quinine-based and quinidine-based catalysts. In certain embodiments, the quinine-based and quinidine-based catalysts contain a hydroxy group at the 6′ position. In certain embodiments, the quinine-based and quinidine-based catalysts contain an O-aryl group or an O-aroyl group at the C9 position. In certain embodiments, the quinine-based and quinidine-based catalysts contain an optionally substituted O-diazene group or an optionally substituted O-benzoyl group at the C9 position. In certain embodiments, the quinine-based and quinidine-based catalysts contain a thiourea at the C9 position. In certain embodiments, the quinine-based and quinidine-based catalysts contain an NH(═S)NH-aryl group at the C9 position. Another aspect of the present invention relates to a method of preparing a chiral, non-racemic compound from a prochiral electron-deficient alkene or prochiral imine, comprising the step of: reacting a prochiral alkene or imine with a nucleophile in the presence of a catalyst; thereby producing a chiral, non-racemic compound; wherein said catalyst is a derivatized quinine or quinidine. In certain embodiments, the nucleophile is a malonate or β-ketoester. In certain embodiments the nucleophile is an alkyl or aryl or aralkyl 2-cyano-2-alkylacetate. In certain embodiments the nucleophile is an alkyl or aryl or aralkyl 2-cyano-2-alkylacetate. Another aspect of the present invention relates to a method of kinetic resolution, comprising the step of: reacting a racemic aldehyde or racemic ketone with a nucleophile in the presence of a derivatized quinine or quinidine, thereby producing a non-racemic, chiral compound. In certain embodiments, the kinetic resolution is dynamic.